A group of Venrock Healthcare Capital Partners entities and affiliated persons filed a Form 4 with the SEC on November 4, 2026, disclosing the purchase of 8,305 shares of common stock in Lycia Therapeutics, Inc. (NASDAQ:LYCA) on November 2, 2026.

Key Highlights

  • Transaction date: 8,305 shares of common stock were acquired on November 2, 2026.
  • Weighted average price: $26.95 per share, with individual transactions ranging from $26.60 to $27.00 inclusive.
  • Post-transaction beneficial ownership: 6,858,542 shares of common stock held indirectly by the reporting group following the transaction.
  • Share breakdown of purchase: 3,775 shares acquired by VHCP3, 378 shares by VHCP Co-Investment Holdings III, LLC, and 4,152 shares by Venrock Healthcare Capital Partners EG, L.P.
  • Reporting persons: Nine reporting persons are listed, including Venrock Healthcare Capital Partners III, L.P., VHCP Management III, LLC, Bong Y. Koh, and Nimish P. Shah, all c/o Venrock, 7 Bryant Park, 23rd Floor, New York, NY 10018.
  • Relationship to issuer: Each reporting person is identified as a 10% Owner.

Venrock Healthcare Group Adds to Lycia Therapeutics Position on November 2, 2026

According to the filing, Venrock Healthcare Capital Partners III, L.P. and affiliated entities acquired a combined 8,305 shares of Lycia Therapeutics, Inc. common stock on November 2, 2026. The weighted average purchase price was $26.95 per share, and the filing notes that the securities were purchased in multiple transactions at prices ranging from $26.60 to $27.00 inclusive. The reporting persons stated they will provide full information on the number of shares purchased at each separate price within that range upon request by the issuer, any security holder, or the SEC staff.

The filing disclosed that the 8,305 shares were distributed across three entities: 3,775 shares held by Venrock Healthcare Capital Partners III, L.P. (VHCP3), 378 shares held by VHCP Co-Investment Holdings III, LLC (VHCP Co-3), and 4,152 shares held by Venrock Healthcare Capital Partners EG, L.P. (VHCP EG). Following the transaction, the aggregate beneficial ownership reported by the group stood at 6,858,542 shares, consisting of 1,773,271 shares held by VHCP3, 177,470 shares held by VHCP Co-3, 4,256,011 shares held by VHCP EG, and 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. (VHCP XP).

The filing further explained the management and ownership structure. VHCP Management III, LLC is identified as the general partner of VHCP3 and the manager of VHCP Co-3. VHCP Management EG, LLC is the general partner of VHCP EG, and VHCP Management XP, LLC is the general partner of VHCP XP. Bong Y. Koh and Nimish P. Shah are identified as voting members of each of these management entities. The filing states that each management entity and each of Messrs. Koh and Shah "expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein." All beneficial ownership is reported as indirect, held by funds.

What Was Disclosed

The filing reported the purchase of 8,305 shares of Lycia Therapeutics common stock by Venrock-affiliated entities on November 2, 2026, at a weighted average price of $26.95, bringing the group's total indirect beneficial ownership to 6,858,542 shares.